A proprietary pipeline of in house projects focused on CNS disorders.

Ksilink’s objective is to deliver pre-clinical candidates (PCC) through proprietary programs or through strategic collaborations.

Phenotypic drug discovery allows for exploring shared etiologies of rare diseases as gateways to much  larger patient groups. We develop novel treatment options of different modalities for diseases with a high medical need.

Our pipeline is completed with research driven programs with support from national and EU consortia to become next generation drug discovery programs.